Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease Authors: Jeong Hwa Lee, Hae Chang Cho, Jae Myung Cha, Byong Duk Ye, Sung Wook Hwang, Eun Soo Kim Published: 2026 ABSTRACT AbstractUpadacitinib, a selective Janus kinase 1 inhibitor, has demonstrated efficacy in moderate-to-severe inflammatory bowel disease (IBD). Although its safety profile has been well established, genitourinary adverse events have rarely been reported. We present the first case series of semen discoloration associated with upadacitinib use in patients with ulcerative colitis and Crohn's disease. We retrospectively reviewed the medical records of six male IBD patients who developed semen discoloration during upadacitinib therapy at four referral hospitals in South Korea. Data on symptom onset, severity, and persistence were collected and analyzed. All six patients exhibited bluish or greenish semen after a median of 2 months of daily therapy with 45 mg upadacitinib. None of the patients exhibited urologic symptoms or infectious causes. Three patients reported reduced intensity and frequency of discoloration after the dose was reduced to 30 mg, while two achieved complete resolution following dose reduction to 15 mg or drug discontinuation. Urologic evaluations, including semen analysis, revealed no abnormalities. This is the first report documenting semen discoloration as a potential adverse event of upadacitinib therapy in IBD. Semen discoloration appears to be a rare, dose-related, and reversible adverse event associated with high-dose upadacitinib therapy. Further studies are needed to clarify the underlying mechanisms and long-term clinical implications.Keywords: Inflammatory bowel diseases, Upadacitinib, Semen discoloration, Case reports INTRODUCTION Upadacitinib, an oral selective Janus kinase (JAK) 1 inhibitor, has been approved for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD). Its mechanism of action involves modulation of pro-inflammatory cytokine signaling through the JAK–STAT pathway, resulting in effective induction and maintenance of remission in refractory inflammatory bowel disease (IBD).1-4 Upadacitinib has demonstrated a generally manageable safety profile, with the most commonly reported adverse events including infections (e.g., upper respiratory tract infections and herpes zoster), abnormalities in laboratory tests (elevations in lipid parameters, transaminases, and creatine kinase), cytopenias, and gastrointestinal symptoms.5 Genitourinary adverse events have rarely been reported with JAK inhibitor therapy. To date, no published literature has documented semen discoloration associated with JAK inhibitors, including upadacitinib. However, pharmacovigilance data from the Food and Drug Administration Adverse Event Reporting System identified five reports of semen discoloration among 1,917 upadacitinib-related adverse events in patients with IBD.6,7 Further details—such as color, intensity, associated symptoms, or potential dose relationship—were not provided. Anecdotal cases have also been shared on social media platforms such as Reddit, although these lacked clinical verification and treatment details.8 Here, we present the first case series of six patients with IBD treated at four referral hospitals in South Korea who developed bluish or greenish semen discoloration during upadacitinib therapy, providing detailed clinical information and dose-related observations. This report was approved by the Asan Medical Center Institutional Review Board (IRB number: 2025-1136), and written informed consent was obtained from all participants. CASE PRESENTATION 1. Case 1 A 44-year-old man was diagnosed with extensive moderate UC in May 2022. He had previously been treated with 5-aminosalicylic acid (5-ASA), azathioprine (AZA), vedolizumab, and infliximab. He had previously experienced two episodes of drug-induced pancreatitis: one associated with 5-ASA and the other with AZA. At the initiation of upadacitinib 45 mg in December 2024, sigmoidoscopy revealed a Mayo endoscopic subscore (MES) of 2 and an Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score of 5, with fecal calprotectin (FC) of 2,603 µg/g. One month later, he noted bluish semen discoloration (visual analog scale [VAS] score of 8) (Fig. 1A). The symptom persisted until a dose reduction to 30 mg after 4 months, at which point the discoloration became lighter and intermittent (VAS score of 4) (Fig. 1B). He reported no urologic symptoms. Urinalysis and semen analysis were unremarkable. He continued therapy at 30 mg and achieved both clinical and endoscopic response. (A) Visual analog scale (VAS) of semen discoloration. (B-D) Representative images of semen discoloration ranging from bluish to greenish hues during upadacitinib treatment in patients with inflammatory bowel disease. 2. Case 2 A 22-year-old man with a 2-year history of CD (Montreal classification A1L3B1p) had previously been treated with AZA, infliximab, ustekinumab, and adalimumab. He initiated upadacitinib 45 mg daily in August 2024 for moderate disease activity (Crohn's Disease Activity Index [CDAI] 277.7; FC 2,199 µg/g). After 2 months of therapy, he reported bluish semen discoloration (VAS score of 4), which persisted until a dose reduction to 30 mg in November 2024. Following this reduction, the symptom became less intense and intermittent. Clinical remission was maintained. 3. Case 3 A 26-year-old man with a 9-year history of CD (Montreal classification A1L1B2) had previously been treated with AZA, infliximab, ustekinumab, and vedolizumab. Upadacitinib 45 mg daily was initiated in December 2024 for disease relapse (CDAI 337.3; FC 305 µg/g). After 1 month of therapy, he noted bluish semen discoloration (VAS score of 5). The symptom became less frequent and faded following a dose reduction to 30 mg. No other symptoms were reported. He remained in clinical remission on 30 mg maintenance therapy (CDAI 121; FC 37 µg/g). 4. Case 4 A 51-year-old man with left-sided UC, diagnosed in May 2014, had previously been treated with infliximab, which was discontinued due to loss of response. Upadacitinib 45 mg daily was initiated in December 2024 (MES 3; UCEIS 5; FC 3,283 µg/g). After 4 months of therapy, he reported bluish semen discoloration (VAS score of 6) (Fig. 1C). Due to inadequate clinical response, upadacitinib was discontinued, after which the semen discoloration resolved completely. 5. Case 5 A 48-year-old man with extensive UC, diagnosed in August 2024 and without prior biologic exposure, initiated upadacitinib 45 mg in October 2024. His medical history included 5-ASA-induced pericarditis. After 2 months of therapy, he developed bluish semen discoloration (VAS score of 4). Given his clinical remission and semen discoloration, the dose was reduced to 15 mg in January 2025, leading to complete symptom resolution. 6. Case 6 A 53-year-old man with left-sided UC, diagnosed in October 2021, had previously been treated with 5-ASA, AZA, methotrexate, infliximab, and vedolizumab. In June 2025, he initiated upadacitinib 45 mg daily (C-reactive protein 5.65 mg/dL; FC 874 µg/g; MES 2; UCEIS 7). After 4 weeks, clinical markers improved (FC 279 µg/g), but the patient reported greenish semen discoloration (VAS score of 6) (Fig. 1D), which persisted through August 2025 while he remained on the 45 mg induction dose. DISCUSSION Clinical information from patients who self-reported semen discoloration was systematically reviewed using electronic medical records. The review included disease type and status, prior biologics exposure, upadacitinib dose, timing of onset, and changes in severity in relation to dose adjustments. The degree of discoloration was assessed using a color-based VAS developed specifically for this case series. This scale consisted of a 0–10 gradient ranging from normal semen color to maximal discoloration, generated using an initial patient-provided photograph as a reference. All scores were independently assigned by the patients, and no standardized color chart or additional photographic documentation was used. In this case series, a clear temporal association was observed between upadacitinib administration and semen discoloration, which developed after a median duration of 2 months (range, 1 to 4 months) of daily 45 mg therapy (Table 1). The discoloration either partially or completely resolved following dose reduction or treatment discontinuation, strongly suggesting a dose-dependent and reversible effect. Urologic evaluations and laboratory investigations were unremarkable, effectively excluding other common causes such as infections or hematospermia. Table 1Clinical Summary of Six IBD Patients with Semen Discoloration during Upadacitinib TherapyPatientAge, yrIBD typeUPA dose, mgTime to symptom onset, moSemen discolorationDose change after discoloration, mgPersisted or resolvedAssociated symptoms144UC451Bluish (VAS 8)30Partially resolved (VAS 4)None222CD452Bluish (VAS 4)30Partially resolved (VAS 2)None326CD451Bluish (VAS 5)30Partially resolved (VAS 2)None451UC454Bluish (VAS 6)DiscontinuedResolvedNone548UC452Bluish (VAS 4)15ResolvedNone653UC451Greenish (VAS 6)45 (no dose reduction)No changeNoneIBD, inflammatory bowel disease; UPA, upadacitinib; UC, ulcerative colitis; CD, Crohn’s disease; VAS, visual analog scale. Clinical Summary of Six IBD Patients with Semen Discoloration during Upadacitinib Therapy IBD, inflammatory bowel disease; UPA, upadacitinib; UC, ulcerative colitis; CD, Crohn’s disease; VAS, visual analog scale. Although semen discoloration is a rare adverse event, several cases have been identified in South Korea within a relatively short period after the drug’s approval, whereas reports from Western countries remain limited despite earlier availability of upadacitinib. This difference may simply reflect variations in reporting practices or clinical recognition rather than a true biological distinction. Nonetheless, prior studies have suggested that certain adverse events of upadacitinib, such as acne and herpes zoster, may occur more frequently in Asian populations, raising the possibility that population-specific factors could influence the occurrence or reporting of rare events.9-11 However, in the absence of mechanistic evidence and with the nature of the discoloration itself remaining unclear, any conclusions regarding ethnic or regional predisposition should be interpreted cautiously. Larger, multiethnic studies will be required to determine whether this observation represents a true population-related phenomenon or simply reflects differences in surveillance and reporting. Given the apparent dose dependency, semen discoloration may not be encountered in rheumatologic diseases, where upadacitinib is typically administered at a lower dose of 15 mg. Nevertheless, the underlying mechanism remains unclear. One hypothesis is that direct drug excretion, metabolite accumulation, or pigment deposition may contribute to altered seminal fluid color. This is supported by microscopic findings in one patient (Case 1), in whom compound aggregation suggestive of drug material, metabolites, or pigment was observed during urological examination. Notably, semen analysis in the same case demonstrated normal sperm count and motility, indicating that this adverse event does not appear to impair male reproductive function. Despite its benign clinical course, semen discoloration may provoke significant anxiety among affected patients. Such concern could lead to reluctance in adhering to prescribed therapy, potentially compromising disease control or prompting unnecessary changes to effective medications. Therefore, clinicians should be aware of this phenomenon, provide reassurance, and offer appropriate counseling to support treatment adherence. Patients should be informed that semen discoloration associated with upadacitinib appears to follow a benign and reversible course, with no evidence of impaired reproductive function in the cases observed. The discoloration may lessen with dose reduction and has been reported to resolve completely after discontinuation of therapy. Clinicians should also advise patients to seek further evaluation if urinary symptoms such as dysuria, frequency, urgency, or hematuria or systemic manifestations, including fever or chills, develop, as these may indicate a urinary tract infection or other conditions requiring additional assessment. Across the four centers where cases were identified, 323 patients received upadacitinib, including 181 male patients, among whom six developed semen discoloration. This corresponds to an estimated incident rate of approximately 3.3% within this restricted cohort. Although the calculated rate implies that the event is uncommon, this interpretation remains tentative given the methodological limitations of the dataset. This study has some limitations, including its small sample size, retrospective design, and absence of standardized biochemical semen analyses. Additionally, the incidence rate was calculated only within centers where cases were recognized, which may overestimate the true frequency. Nonetheless, it represents the first formal documentation of semen discoloration associated with upadacitinib use in IBD and underscores the need for further investigation to elucidate the underlying mechanisms, assess its long-term clinical significance, and explore potential ethnic susceptibility. In conclusion, semen discoloration may represent a rare, dose-related, and reversible adverse event of upadacitinib therapy in patients with IBD. Awareness of this phenomenon is essential for patient communication and clinical decision-making. Further studies are warranted to clarify its mechanisms and clinical relevance. Footnotes CONFLICTS OF INTEREST E.S.K. is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported. AUTHOR CONTRIBUTIONS Data acquisition: H.C.C., J.M.C., B.D.Y., S.W.H., E.S.K. Drafting of the manuscript: J.H.L., H.C.C., J.M.C. Critical revision of the manuscript for important intellectual content: B.D.Y., S.W.H., E.S.K. Study supervision: S.W.H., E.S.K. Approval of final manuscript: All authors. DATA AVAILABILITY STATEMENT The data underlying this article will be made available by the corresponding author upon reasonable request. REFERENCES